Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
Apr 23, 2025
Contract Type
partnership
South San FranciscoBiotechnologyHealth CareGeneticsTherapeutics
Description
Epicrispr Biotechnologies has announced a partnership with Springbok Analytics to incorporate advanced, AI-driven muscle MRI imaging and analysis into its first-in-human clinical trial of EPI-321, a potential first-in-class treatment for facioscapulohumeral muscular dystrophy (FSHD). The partnership aims to enhance early signal detection and inform the development of the therapy through Springbok's advanced MRI-based muscle analytics.
Company Information
Company
Epicrispr Biotechnologies
Location
7000 Shoreline Court
South San Francisco, California, United States
About
Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases. Their lead program, EPI-321, is a first-in-class disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). The company aims to advance innovative treatments that address the underlying causes of genetic disorders. With recent funding, Epicrispr is entering the clinical stage to bring much-needed therapies to patients.
Predictive Intelligence
Strategic
ML-powered predictions for Epicrispr Biotechnologies's next move